In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

Sarclisa is one of two late-stage programmes that Sanofi is hoping will continue a renaissance for its cancer business along with Libtayo (cemiplimab ... being tested for cervical and non ...

A mother of three was blindsided by a cervical cancer diagnosis just days before her 30th birthday — despite experiencing ...

Here are 5 important questions to ask if you’ve been told you have cervical dysplasia: ...

With proper screening, vaccination, and awareness, we can significantly reduce cervical cancer cases. It is crucial to educate people because cervical cancer is one of the few cancers in women ...

A new report explores the disproportionately high death rate among Black women in the Delta from cervical cancer.

A new research paper was published in Oncoscience's Volume 12 on January 20, 2025, titled "Maternal, delivery and neonatal outcomes in women with cervical cancer. A study of a population database." ...

A new research paper was published in Oncoscience’s Volume 12 on January 20, 2025, titled “Maternal, delivery and neonatal ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Dec. 5, 2024 — Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment ... Cervical Cancer Deaths in Young ...

NHS England has promised to eliminate cervical cancer by 2040. Women aged 25-49 are encouraged to have a screening every three years, while women aged 50-64 should have one every five years.